NASDAQ:DMAC   DiaMedica Therapeutics Inc.
A analysis of DMAC in a multi-year chart run to see if market downward pressure is substantial enough overshadow the upcoming catalyst for DMAC in the coming weeks.
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.